NeurAxon Announces Positive Phase 1 Trial Data on NXN-188 for Migraine

-Company Plans Phase 2 Clinical Trial to Commence in Third Quarter-

WALTHAM, MA. August 14, 2007 – NeurAxon, Inc., a developer of next generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced positive data from its Phase 1 clinical trial for NXN-188 assessing the safety and establishing the pharmacokinetic profile of the investigational drug candidate. NXN-188 is a first-in-class, dual-action, small molecule that is being developed for the treatment of acute migraine and which incorporates both 5-HT agonism (the mechanism of action of triptans, the current standard of care in migraine therapy) and nNOS inhibition. NOS is a validated target for migraine therapy as migraine models indicate that nNOS inhibition can relieve pain. Additionally, nitric oxide induces migraines in migraineurs, while the inhibition of NOS has been demonstrated to relieve migraine pain.

The NXN-188 Phase 1 trial was a randomized, double-blind, placebo-controlled dose escalation study which enrolled healthy volunteers. In the study, nine dose levels were evaluated with subjects receiving single oral doses of either NXN-188 or placebo. Subjects were monitored for adverse events and pharmacokinetic parameters. Results from the trial indicate that NXN-188 was well tolerated, with no drug-related adverse events reported.

“Based on the results of this study, in the third quarter of this year we plan to advance NXN-188 into a Phase 2a clinical proof-of-concept study, which will begin to determine the efficacy and product profile of this candidate,” said Robert Medve, M.D., Chief Medical Officer of NeurAxon. “Preclinical studies comparing NXN-188 to triptans, the current standard of care in migraine therapy, demonstrated that NXN-188 has multiple potential advantages over triptan therapy. These benefits may include increased efficacy, tolerability, safety, treatment window, response rates and reduced rebound headache.

“Therefore, we believe that a dual action nNOS inhibitor and 5-HT agonist such as NXN-188 could play a significant role in the $3 billion acute migraine market by addressing migraine patients that do not receive complete relief from triptans and thereby potentially expanding the patient population for migraine therapeutics,” concluded Dr. Medve.

About NXN-188
NXN-188 is a first-in-class, dual-action small molecule incorporating both nNOS inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

About NeurAxon Inc.
NeurAxon Inc. (www.nrxn.com) is a leader in discovering and developing next generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

Corporate Communications Contact:
Chris Erdman
MacDougall Biomedical Communications
508.647.0209 x14